biotech · Post Traumatic Stress Disorder · Prosthetic Joint Infection · ADPT
Adaptive Biotechnologies
Adaptive Biotechnologies Corp
Adaptive Biotechnologies is a biotech organization headquartered in Seattle, USA. It trades on NYSE under ticker ADPT. Primary therapeutic focus areas include Post Traumatic Stress Disorder, Prosthetic Joint Infection, O
1165 Eastlake Ave E, Seattle, Washington 98109, US HQ
2009 Founded
659 Employees
Public company Type
ADPT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1165 Eastlake Ave E, Seattle, Washington 98109, US
- Founded
- 2009
- Employees
- 659
- Programs
- 19
- Drugs
- 23
- Patents
- 12
Obinutuzumab
Phase 2 · mab · Mantle Cell Lymphoma
Obinutuzumab for Mantle Cell Lymphoma is a Phase 2 program (mab) at Adaptive Biotechnologies Corp with 1 ClinicalTrials.gov record(s).
Internal code 232516
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Adaptive Biotechnologies Corp
- Phase
- Phase 2
- Modality
- mab
- Indication
- Mantle Cell Lymphoma
- Status
- active
- Trials
- 1